Gallman Cari, Executive Vice President and General Counsel at Bristol Myers Squibb, has reported significant stock transactions in a recent SEC filing. This filing is crucial as it sheds light on the ongoing compensation practices and equity management strategies at the company.
The filing, dated October 5, 2026, reveals that Cari acquired 4,559 shares of common stock on October 2, 2026, through the exercise of restricted stock units. Additionally, 2,332 shares were withheld to cover tax obligations upon the vesting of these units. This transaction is a reflection of the company's approach to aligning executive compensation with shareholder interests.
Background
Bristol Myers Squibb Co, identified by the CIK 0000014272, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company focuses on innovative medicines and has a significant presence in the life sciences industry. Recent filings indicate that Bristol Myers Squibb is committed to maintaining transparency in its executive compensation practices.
What the Filing Says
The SEC filing states, "These restricted stock units vested in three equal installments beginning on October 2, 2024." This indicates a structured approach to executive compensation, ensuring that executives are rewarded based on performance over time.
Impact
This filing may affect various stakeholders, including shareholders and potential investors, as it highlights the company's commitment to aligning executive rewards with performance. Additionally, it reflects broader industry practices in the pharmaceutical sector, where executive compensation is often tied to stock performance and company success.
What's Next
The filing does not say what happens next.